The United States Food and Drug Administration (FDA) has approved updated labeling for the protease inhibitor atazanavir sulfate (Reyataz) that includes dose recommendations for pregnant women infected with human immunodeficiency virus 1 (HIV-1). The drug was approved to treat HIV-1 infection in 2003.
The United States Food and Drug Administration (FDA) has approved updated labeling for the protease inhibitor atazanavir sulfate (Reyataz) that includes dose recommendations for pregnant women infected with human immunodeficiency virus 1 (HIV-1). The drug was approved to treat HIV-1 infection in 2003.
The updated labeling supports the recommended adult dose of 300 mg of atazanavir boosted with 100 mg of ritonavir. The combination achieved minimum plasma concentrations during the third trimester of pregnancy that were comparable to concentrations observed in historical data on HIV-infected adults. The update is based on data from a multicenter, open-label, prospective, single arm, pharmacokinetic study (Study 182) of 41 HIV-infected pregnant women between 12 and 32 weeks’ gestation.
Available human and animal data suggest that atazanavir doesn’t increase the overall risk of major birth defects compared with the background rate. Because studies in humans can’t rule out the risk of harm, atazanavir should be used during pregnancy only if the benefit outweighs the risk. Patients should be monitored for adverse effects for 2 months postpartum because atazanavir concentrations may rise during this period. Atazanavir should not be used without ritonavir in pregnant or postpartum women.
In patients taking atazanavir, including pregnant women, hyperbilirubinemia often occurs. Neonates exposed to atazanavir in utero should be monitored for severe hyperbilirubinemia during the first few days of life. The drug is not indicated for preventing maternal-fetal transmission of HIV-1.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
2 Commerce Drive
Cranbury, NJ 08512